Satterlee Andrew B, Rojas Juan D, Dayton Paul A, Huang Leaf
Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7571, USA.; UNC and NCSU Joint Department of Biomedical Engineering, Chapel Hill, NC 27599.
UNC and NCSU Joint Department of Biomedical Engineering, Chapel Hill, NC 27599.
Theranostics. 2017 Jan 1;7(2):253-269. doi: 10.7150/thno.16681. eCollection 2017.
Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial pressure, and resistant tumor microenvironment. We have developed a combination therapy that can significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis in the tumor center while simultaneously increasing nanoparticle uptake through a treatment-induced increase in the accumulation and retention of nanoparticles in the tumor. The vascular disrupting agent Combretastatin A-4 Phosphate (CA4P) is able to increase the accumulation of radiation-containing nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is maintained over several days. We use ultrasound to measure the effect of CA4P in live tumor-bearing mice, and we encapsulate the radio-theranostic isotope Lutetium as a therapeutic agent as well as a means to measure nanoparticle accumulation and retention in the tumor. This combination therapy induces prolonged apoptosis in the tumor, decreasing both the fibroblast and total cell density and allowing further tumor growth inhibition using a cisplatin-containing nanoparticle.
侵袭性促纤维增生性肿瘤因其广泛的间质、高间质压力和抗性肿瘤微环境而 notoriously 难以治疗。我们开发了一种联合疗法,该疗法可通过在肿瘤中心引起大量细胞凋亡,同时通过治疗诱导纳米颗粒在肿瘤中的积累和滞留增加来显著减缓大型、富含间质的肿瘤的生长。血管破坏剂磷酸考布他汀A-4(CA4P)能够增加用于内照射治疗的含辐射纳米颗粒的积累,并且这些递送的放射性同位素的滞留可维持数天。我们使用超声来测量CA4P在荷瘤活小鼠中的作用,并且我们将放射性治疗诊断同位素镥封装为治疗剂以及测量纳米颗粒在肿瘤中的积累和滞留的手段。这种联合疗法在肿瘤中诱导长时间的细胞凋亡,降低成纤维细胞和总细胞密度,并允许使用含顺铂的纳米颗粒进一步抑制肿瘤生长。